COMMUNIQUÉS West-GlobeNewswire

Conavi Medical Corp. Announces Pricing of Public Offering of Common Shares and/or Pre-Funded Warrants
18/12/2025
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES FINAL PROSPECTUS WILL BE ACCESSIBLE ON SEDAR+ TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“ [...]
Coloplast announces changes to Executive Leadership Team
18/12/2025
Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s Interventional Urology business as well as the global People & Culture function. Executive [...]
MUVON Therapeutics Appoints Dr. Christine Günther as Chief Technology Officer
18/12/2025
Zurich, Switzerland, December 18, 2025 – MUVON Therapeutics, a clinical-stage biotechnology company focused on developing a novel platform for the regeneration of skeletal muscle tissue, announces the appointment of [...]
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
18/12/2025
BioNTech has completed its exchange offer to acquire CureVac Acquisition complements BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing In total, [...]
Confo Therapeutics Nominates SSTR5 Agonist Antibody CFTX-2034 as Development Candidate for Post-Bariatric Hypoglycemia
18/12/2025
Candidate selection underscores Confo’s ability to rapidly advance differentiated GPCR-targeting therapeutics and its focus on metabolic and endocrine disorders Ghent, Belgium – December 18, 2025 – Confo Therapeutics , [...]
DXS International plc (AQSE: DXSP): Statement for the 2025 Annual General Meeting
18/12/2025
18 December 2025 DXS INTERNATIONAL PLC (AQSE: DXSP) Statement for the 2025 Annual General Meeting The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and [...]
Sequana Medical Announces Granting of Key Additional U.S. Patent for DSR
18/12/2025
Ghent, Belgium, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Builds upon existing granted DSR patents in US, Europe, Japan and China Strengthens DSR patent protection based upon extensive clinical and pre-clinical experience Data [...]
GlucoModicum unveils Sofio™, the world’s first needle-free glucose monitor based on magneto-hydrodynamics (MHD)
18/12/2025
PRESS RELEASE — FOR IMMEDIATE RELEASE GlucoModicum unveils Sofio™, the world’s first needle-free glucose monitor based on magneto-hydrodynamics (MHD) MHD technology draws micro-sample through skin; glucose is measured [...]
DXS International plc (AQSE:DXSP) Notice of Cyber Security Incident
18/12/2025
18 December 2025 DXS INTERNATIONAL PLC (AQSE: DXSP) Notice of Cyber Security Incident The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital [...]
EssilorLuxottica et Burberry renouvellent leur accord de licence
18/12/2025
EssilorLuxottica et Burberry renouvellent leur accord de licence Paris, France et Londres, Royaume-Uni (18 décembre 2025) – EssilorLuxottica et Burberry ont annoncé aujourd’hui le renouvellement de leur accord de [...]
EssilorLuxottica and Burberry announce licensing partnership renewal
18/12/2025
EssilorLuxottica and Burberry announce licensing partnership renewal Paris, France and London, United Kingdom (18 December 2025) – EssilorLuxottica and Burberry today announced the renewal of their licensing agreement [...]
FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor
18/12/2025
Funding to support Phase 1 clinical development of best-in-class PARG inhibitor candidate FORX-428 FORX-428 is potential new treatment option for patients whose cancers are resistant to, or have become resistant to, [...]
InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
18/12/2025
BEIJING, Dec. 17, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the [...]
New Ebook Offers First-Time Biotech CEOs a Roadmap for the Decisions That Determine Company Success
17/12/2025
Produced by KreaMedica, in partnership with Venture Valuation and Lacerta Bio: three leading advisors to early-stage biotechs MONTREAL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Three of the biotech industry’s trusted advisory [...]
Inventiva présentera à la 44e conférence annuelle J.P. Morgan Healthcare
17/12/2025
Daix (France), New York City (New York, États-Unis ), le 17 décembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference
17/12/2025
Daix (France), New York City (New York, United States), December 17, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the [...]
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
17/12/2025
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific Evidence: The [...]
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
17/12/2025
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug [...]
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
17/12/2025
– End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Overall survival [...]

Pages